What is the best deal structure for NEU?
A higher upfront payment will be paired with a lower revenue/royalty share going forward.
If we believe Trofinetide will be successful then surely we want to retain as large a portion of the future revenue as possible?
Personally, I will be disappointed if it is a large upfront payment at the expense of a larger share of future revenues. I guess it's a case of waiting to see... I have confidence that Dr. Treagus will do what is best for the long-term value of NEU
NASDAQ vs Aussie biotechs and licensing deals, page-5
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.60 |
Change
-0.340(2.13%) |
Mkt cap ! $1.993B | |||
| Open | High | Low | Value | Volume |
| $16.25 | $16.32 | $15.55 | $9.440M | 595.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 3197 | $15.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.68 | 1852 | 1 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |